Emmes has set up a cell and gene therapy research unit to support biopharmaceutical companies developing.
The new center will support cell and gene therapy clinical trials in a range of therapeutic indications.
CEO Christine Dingivan cited both market opportunities and a desire to reorganize Emmes offering in this area as motivations for development of the center.
“Our reputation and the growth opportunities in cell and gene therapy research drove the decision to establish the centre. We have supported more than 125 clinical trials that integrate cell or gene therapies and have a long record of successful collaboration with leading investigators in this field.
“This new center centralizes our resources and facilitates expansion in our current strengths to other high-potential areas where we’re building expertise.”
The cell and gene therapy center fits with the strategy that saw Emmes establish its rare disease center in November last year.
More recently, following the same strategy, Emmes reorganised its ophthalmology trials unit in a move that followed shortly after it bought Milwaukee, Wisconsin-based Clinical Edge.
Cell and gene therapy protocols
Adam Mendizabal, who will lead the cell and gene therapy center, cited Emmes’ experience in cell and gene therapy trials as key to its offering.
“The successful partnerships we’ve built with leading cell and gene therapy experts have resulted in more than 100 scientific manuscripts co-authored by Emmes researchers and centered on research results and progress. “
He added that Emmes has worked with the US National Institutes of Health and biopharma companies to evaluate promising therapeutic approaches in multi-institutional clinical trials to improve the outcomes.
He predicted, “Emmes’ Cell and Gene Therapy Centre will harmonize our diverse credentials across multiple therapeutic areas and functions under one roof, allowing our best practices and expertise to be leveraged even more efficiently in this complex environment.”